MedTrace Logo

AI-Supported Occupational Therapy for Handwriting

NCT06871566 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-03-12

No results posted yet for this study

Summary

Aim: This study investigates the impact of an AI-supported occupational therapy program, developed using the Model of Human Occupation (MOHO), on handwriting skills in children at risk for Developmental Coordination Disorder (DCD).

Method: A randomized controlled trial was conducted with 42 children aged 8-12 years, identified as being at risk for DCD using the Developmental Coordination Disorder Questionnaire (DCDQ). Participants were randomized into an intervention group (n=21) and a control group (n=21). The intervention group received an AI-supported occupational therapy program twice weekly for 8 weeks. Handwriting performance was assessed pre- and post-intervention using the Minnesota Handwriting Assessment (MHA).

Keywords: artificial intelligence, occupational

Conditions

  • Occupational Therapy

Interventions

OTHER

Artificial Intelligence-Supported Occupational Therapy Program

The AI-supported occupational therapy program was individually implemented by an occupational therapist over 8 weeks, with 2 sessions per week, each lasting 45 minutes. A touchscreen tablet, touch pen, and external camera were utilized during the sessions. At the beginning of the program, technological devices and artificial intelligence tools were introduced to the children. For the goals and detailed intervention program of the 8-week schedule

Sponsors & Collaborators

  • Hacettepe University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-12
Primary Completion
2024-08-20
Completion
2024-08-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06871566 on ClinicalTrials.gov